Clinical Trial: Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Phase IV, Randomized, Open-Label, Multi-Center Study in Adults: Evaluation of Long-Term Immunogenicity in Subjects Boosted With a New TBE Vaccine for Adults (Free of Protein-Derived Stabilizer) in S

Brief Summary: The purpose of this study it is to evalutate the persistence of antibodies after a booster immunisation with a TBE vaccine for adults

Detailed Summary:
Sponsor: Novartis

Current Primary Outcome: Long-term antibody kinetics as measured both by ELISA and neutralisation test (NT) five years after first booster immunization.

Original Primary Outcome:

Current Secondary Outcome: Booster response in a subset of subjects as measured by NT, ELISA and cellular immunity on Days 3, 5, 7 and 21 after 2nd booster immunization.

Original Secondary Outcome:

Information By: Novartis

Dates:
Date Received: April 3, 2006
Date Started: February 2006
Date Completion:
Last Updated: March 12, 2007
Last Verified: March 2007